Vizz, an eye drop, has been approved by the U.S. Food and Drug Administration (FDA) for treating presbyopia; a condition that makes it difficult to see close objects clearly as people age. One drop has a lasting effect for about ten hours.
Presbyopia is an age-related condition that mostly affects people over forty. When we are young, the lens inside our eye is flexible, changing shape effortlessly, so we can easily focus on closer things. As we get older, that lens naturally stiffens, and the muscles that help it adjust do not work quite as well. This makes it challenging to quickly switch our focus from far-away objects to nearby ones, resulting in blurry vision, making it more difficult to focus on closer objects. According to a research by the American Academy of Ophthalmology in 2018, the global prevalence of presbyopia is estimated at 1.8 billion people worldwide, and is expected to increase to reach 2.1 billion, meaning that about 26% of the global population may suffer from presbyopia. Traditional treatments mostly involve reading glasses or contact lenses.
Aceclidine, the component of Vizz eye drop, is a well-established drug in Europe used for the treatment of glaucoma. In 2025, LENZ Therapeutics announced FDA Approval of VIZZ™ (1.44% aceclidine ophthalmic solution) for the Treatment of Presbyopia. The Approval came after three successful clinical trials, CLARITY 1, CLARITY 2, and CLARITY 3, for its efficacy and safety as a treatment for presbyopia. Vizz helps improve the eyes' ability to focus on close-up objects by extending the depth of focus to enhance near vision significantly without causing a myopic shift. The clinical studies have approved its ability to improve near vision within 30 minutes, with an effect that lasts for up to 10 hours at only one dose daily. The first two trials studied its safety for only 42 days, while the third trial confirmed its safety for over a 6-month study.
.png)
The study's results
(adopted from LENZ Topline CLARITY Results Phase 3 Clinical Trials report)
Vizz eye drop is mostly well-tolerated, but some adverse reactions may occur, and most of them were mild, transient, and self-resolving. The most commonly reported adverse reactions include instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in more than 5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%).
Vizz is expected to be released in the United States of America by the end of 2025, with plans for global distribution later on. This transformative medication can help improve the quality of life of millions of presbyopia patients worldwide, as it is a noninvasive, well-tolerated, fast-acting, with a long-lasting effect, a one drop daily acting within 30 minutes and lasts for up to 10 hours, what a relief!
References
ncbi.nlm.nih.gov
https://d1io3yog0oux5.cloudfront.net/_68095b03e64085be9c03cc265854cbbf/lenztx/db/2271/21447/pdf/Clarity+Topline+Presentation+Slides+04022024+final+locked.pdf